Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 233

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 233
---
 converts to one share of common stock.

 F-20

Stock OptionsThe Company has granted stock options which (i) vest fully on the date of grant; (ii) vest 25% on the one-year anniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter; or (iii) vest quarterly over one-year, for grants to Board of Directors, officers and employees. Stock options have a maximum term of 3 or 10 years.The activity related to stock options during the year ended December 31, 2024 is summarized as follows: 

        Shares

        Weighted-average Exercise Price

        Weighted-average Remaining Contractual Term (Years)

        Outstanding at December 31, 2023

        64

        $
        3,555.83

        Granted

        —

        —

        Exercised

        —

        —

        Expired and forfeited

        —

        —

        Outstanding at December 31, 2024

        64

        $
        3,555.83

        5.8

        Exercisable at December 31, 2024

        64

        $
        3,555.83

        5.8

      For the year ended December 31, 2023, the weighted-average Black-Scholes value per stock option issued during 2023 was $516.21. The fair value of the stock options was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: 

        Volatility

        144.2
        %

        Expected term (years)

        5.04

        Risk-free interest rate

        3.60
        %

        Expected dividend yield

        0.0
        %
       
       Expected volatility is based on the historical volatility of shares of the Company’s common stock. In determining the expected term of stock options, the Company uses the “simplified” method. Under this method, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the stock options in effect at the time of the grants. The dividend yield assumption is based on the expectation of no future dividend payments by the Company. In addition to assumptions used in the Black-Scholes model, the Company reduces stock-based compensation expense based on